Aktienanalyse zu IM Cannabis Corp (IMCC)IMCCIM Cannabis Corp

IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower. It operates in the Consumer Non-Cyclicals sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).

IM Cannabis Corp is not a good buy right now due to its current price of $3.41, a year-to-date change of -92.37%, and ongoing financial losses. The company's gross margin has dropped to 19.83% in Q2 2026, indicating declining profitability. Additionally, the stock is under pressure from Nasdaq compliance issues, which could further impact its liquidity and market perception.